{"id":"botulinum-toxin-type-a-44u","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dry mouth"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting acetylcholine release, botulinum toxin Type A (44U) reduces muscle spasms and contractions, providing therapeutic benefits in various indications.","oneSentence":"Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:45.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy"},{"name":"Cervical dystonia"}]},"trialDetails":[{"nctId":"NCT01189760","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-01","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":917},{"nctId":"NCT01797094","phase":"PHASE3","title":"BOTOX® in the Treatment of Upper Facial Lines in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-02","conditions":"Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":101},{"nctId":"NCT01224015","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":684}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®"],"phase":"phase_3","status":"active","brandName":"botulinum toxin Type A (44U)","genericName":"botulinum toxin Type A (44U)","companyName":"Allergan","companyId":"allergan","modality":"Biologic","firstApprovalDate":"","aiSummary":"Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction. Used for Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy, Cervical dystonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}